MET-amplified (MKN45) and MET-overexpressed (H441) xenograft models of CCA were used to further the preclinical development of an orally bioavailable small-molecule inhibitor LY2801653 targeting MET kinase leading to in vivo anti-tumor effects and in vivo vessel normalization effects (3). This evidence concerns the gene MET and cholangiocarcinoma.